HQY241018C80000
- 7.95
- +0.03+0.38%
HealthEquity Newsroom
Barclays Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $104
Barclays Reaffirms Their Buy Rating on Healthequity (HQY)
J.P. Morgan Maintains HealthEquity(HQY.US) With Buy Rating, Cuts Target Price to $106
BofA Securities Maintains HealthEquity(HQY.US) With Buy Rating
Wells Fargo Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $110
Navigating 8 Analyst Ratings For HealthEquity
Barrington Research Maintains Outperform on HealthEquity, Maintains $105 Price Target
Barrington Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $105
HealthEquity: Strong Buy Rating on Robust Financial Performance and Favorable Outlook
RBC Capital Maintains HealthEquity(HQY.US) With Buy Rating, Raises Target Price to $100
Analysts' Top Healthcare Picks: Agios Pharma (AGIO), Healthequity (HQY)
KeyBanc Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $100
Wells Fargo Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $110
A Quick Look at Today's Ratings for HealthEquity(HQY.US), With a Forecast Between $100 to $110
HealthEquity Analyst Ratings
HealthEquity Is Maintained at Buy by Deutsche Bank
HealthEquity Price Target Maintained With a $92.00/Share by RBC Capital
A Quick Look at Today's Ratings for HealthEquity(HQY.US), With a Forecast Between $92 to $110
HealthEquity (HQY) Maintains Strong Buy Rating Amidst Growth and Positive Financial Outlook
JMP Securities Reaffirms Their Buy Rating on Healthequity (HQY)